# Skyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's Disease

- Source: PR Newswire M&A
- Published: 2026-11-05T19:24:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-first-us-patients-dosed-in-pivotal-falcon-hd-study-evaluating-sky-0515-in-huntingtons-disease-302931241.html
- Canonical: https://groundlevelnews.com/story/skyhawk-therapeutics-announces-first-u-s-patients-dosed-in-pivotal-fal-a1572e/

More than 50,000 doses of SKY-0515 have now been administered to patients. BOSTON, Nov. 5, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced that the first U.S....

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._